• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Polyrizon Ltd.

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
July 22, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Retains Nasdaq Listing Following Hearings Panel
July 15, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
June 12, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Receipt of Nasdaq Delisting Notice
May 23, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
May 21, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
May 13, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
April 25, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
April 11, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
April 02, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
April 01, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Ltd. Announces $17.0 Million Private Placement
March 31, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
March 27, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
March 25, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
March 14, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
March 13, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
March 11, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
March 10, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
January 30, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
January 23, 2025
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
December 30, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
December 19, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
December 18, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
December 13, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
December 02, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
October 28, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap